TANGO

Tango’s INTEGRATE 2024 Underscores the Vital Role of Integrated Energy and Sustainability in Today’s Business and Regulatory Environment

Retrieved on: 
Tuesday, May 7, 2024
Risk management, Built environment, Partnership, Conference, Carbon, CSRD, BPS, Disclosure

The conference centered on the critical theme of integrating energy and sustainability within businesses in a data-driven, pragmatic, and action-oriented manner.

Key Points: 
  • The conference centered on the critical theme of integrating energy and sustainability within businesses in a data-driven, pragmatic, and action-oriented manner.
  • "Risk management and energy pragmatism are crucial for businesses to operate efficiently in today’s complex sustainability and regulatory environment", stated Andy Anderson, Tango’s EVP of Energy and Sustainability Solutions and Chief Sustainability Officer.
  • Identifying and Executing Decarbonization Opportunities - The second panel covered diverse perspectives on the scalable approaches to decarbonization.
  • Discussions at INTEGRATE underscored the vital role of integrated energy and sustainability practices in today’s business and regulatory environment and illustrated the practical applications of the data-driven, pragmatic approach to sustainability that WatchWire by Tango champions.

Tango Will Be Carbon Neutral by 2030, According to First Annual Sustainability Report

Retrieved on: 
Tuesday, April 9, 2024
Sustainability studies, Culture, EVP, Environment, ESG, ISSB, Disclosure, Carbon, GRI, Investment, Energy, Ecosystem, Marketing, Renewable energy

DALLAS, April 09, 2024 (GLOBE NEWSWIRE) -- Tango has released its first Sustainability Report for 2023, marking an important step in their sustainability journey.

Key Points: 
  • DALLAS, April 09, 2024 (GLOBE NEWSWIRE) -- Tango has released its first Sustainability Report for 2023, marking an important step in their sustainability journey.
  • In the report, Tango announced their goal of becoming carbon neutral by 2030, setting them apart as a pioneer in the larger ecosystem of real estate technology providers.
  • As a technology service provider, most of Tango’s carbon footprint stems from the products they offer, the IT infrastructure, and the data operations.
  • In addition to their focus on environmental and climate impact, Tango’s Sustainability Report highlights their diverse staff and seamless teamwork as being their most valuable asset.

Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Monday, April 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Employment, Compensated emancipation, RSU, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective April 1, 2024, the Compensation Committee of Tango Therapeutics' Board of Directors granted a non-qualified stock option to purchase 139,453 shares of its common stock and 23,698 restricted stock units (RSUs) to a new employee under Tango Therapeutics' 2023 Inducement Plan.
  • The Tango Therapeutics 2023 Inducement Plan is used exclusively for the grant of equity awards to individuals as an inducement material to such individual's entering into employment with Tango Therapeutics, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.
  • The options have an exercise price of $7.64 per share, which is equal to the closing price of Tango Therapeutics' common stock on April 1, 2024.
  • The options and RSUs are subject to the terms and conditions of Tango Therapeutics' 2023 Inducement Plan, which was approved in February 2023, and the terms and conditions of the stock option and RSU agreements covering the grant.

Tango Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Monday, March 18, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ODD, Cancer, Research, PRMT5, Brain, Mutation, BRCA, NSCLC, NYU Langone Health, Breast, General counsel, Patient, GBM, Orphan, Collaboration, DNA, DevOps, MTAP, Sarcoma, Head, MTA, AACR, Glioblastoma, Clinical trial, PARP, Therapy, Drug development, ATM, ACS, Safety, Pharmacokinetics, Carcinoma, Corporate governance, FDA, American Chemical Society, Food, Pharmaceutical industry

Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.

Key Points: 
  • Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the fourth quarter and full year ended December 31, 2023, and provided business highlights.
  • “In 2023, we made meaningful progress developing precision oncology treatments and now have four ongoing phase 1/2 clinical trials.
  • The U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) to TNG462 in December 2023 for the treatment of soft tissue sarcomas.
  • The increase is the result of out-licensing a program to Gilead for $5.0 million during the second quarter of 2023.

Tango Networks, the Leader in Business Mobile Telecommunications, Is Excited to Announce the Launch of Its Latest Innovation, Global Pass

Retrieved on: 
Tuesday, March 12, 2024
Technology, Mobile, Wireless, Networks, Telecommunications, Smartphone, Pass, ESIM, UC, Carbon footprint, Communication, Fear, Senior, Network, Geography, Unified communications, BYOD, Multimedia, Mobile phone

Tango Networks today announced Global Pass , a single rate subscription plan for Tango Extend across 39 countries.

Key Points: 
  • Tango Networks today announced Global Pass , a single rate subscription plan for Tango Extend across 39 countries.
  • View the full release here: https://www.businesswire.com/news/home/20240312069630/en/
    Tango Extend Global Pass sets the new benchmark for global business mobile communications under a single subscription plan.
  • Now, with Global Pass, Tango Extend subscribers enjoy a single fixed-rate business mobile service across 14 Home countries with seamless roaming in a further 25 Home Away countries across Europe and North America.
  • Global Pass liberates mobile communication from borders, enabling employees to stay connected effortlessly while traveling or working internationally.

Tango, Leading Provider of Cloud-Based Real Estate and Facilities Management Software, Acquires Locatee

Retrieved on: 
Tuesday, March 5, 2024
Acquisition, Investment, Internet of things, Berkshire Partners, Built environment, Organization, Retail

DALLAS and ZURICH, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Tango, a leading provider of cloud-based real estate and facilities management software, today announced it has acquired Locatee, a leading workplace analytics solution.

Key Points: 
  • DALLAS and ZURICH, Switzerland, March 05, 2024 (GLOBE NEWSWIRE) -- Tango, a leading provider of cloud-based real estate and facilities management software, today announced it has acquired Locatee, a leading workplace analytics solution.
  • Locatee empowers organizations to make fact-based decisions by providing a complete picture of occupancy, driving strategic portfolio decisions, improving operational space utilization, and increasing employee satisfaction.
  • “Organizations are actively seeking to better understand occupancy levels, however existing solutions are often disparate and cost-prohibitive, leaving them struggling to gain accurate insights.
  • Frost Brown Todd LLP acted as advisor and legal counsel to Tango and Berkshire Partners on the acquisition of Locatee.

Tango Survey Findings are a Warning to Employers

Retrieved on: 
Wednesday, February 28, 2024
HR, Census, Online shopping

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Tango, an international leader in digital rewards and payouts, today released findings from a survey conducted with employees to help employers become aware of how non-cash incentives impact whether workers feel appreciated or not. These findings, released a few days ahead of Employee Appreciation Day held on March 1, 2024, show that two-thirds of employees know about the holiday, yet only one-third of them have ever received anything to feel appreciated.

Key Points: 
  • SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Tango, an international leader in digital rewards and payouts, today released findings from a survey conducted with employees to help employers become aware of how non-cash incentives impact whether workers feel appreciated or not.
  • A correlation was shown between awareness of the holiday and excitement for receiving gifts from employers, meaning there’s a real risk of employers disappointing their employees by not getting them anything for the holiday.
  • In addition, the findings highlighted while one in four prefer digital cards over physical, and a similar amount have no preference, in-office workers show greater preference for physical gift cards.
  • To find more results and top findings from the survey, visit Tango’s website .

YourTango Announces Inaugural YourTango Experts Healers and Helpers Virtual Summit

Retrieved on: 
Friday, February 9, 2024
Psychotherapy, Education, Tango (magazine), Hypnotherapy, EST, Loneliness, Mental health, Love, EMDR, Yoga, Knowledge, TED, Nursing

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- Tango Publishing, Inc., creators of YourTango.com and YourTango Experts, a B2B division supporting healing professionals, is thrilled to announce the inaugural Healers and Helpers Summit, a virtual event scheduled for free broadcast from February 14 - 18, 2024. This world-class event offers registrants free access to 24 hours of programming each day beginning at 11:30 a.m. EST. The event aims to inspire and educate a diverse community of healing professionals, providing talks and masterclasses designed to enhance the vital work practitioners do in the areas of mental health, love and relationships, personal growth, and lifestyle wellbeing.

Key Points: 
  • NEW YORK, Feb. 9, 2024 /PRNewswire/ -- Tango Publishing, Inc., creators of YourTango.com and YourTango Experts, a B2B division supporting healing professionals, is thrilled to announce the inaugural Healers and Helpers Summit, a virtual event scheduled for free broadcast from February 14 - 18, 2024.
  • This world-class event offers registrants free access to 24 hours of programming each day beginning at 11:30 a.m. EST.
  • YourTango founder and CEO Andrea Miller remarked, "We urgently need to unite around our healing professionals and provide world-class training, education, and support.
  • By connecting healers and helpers with cutting-edge knowledge and expertise, YourTango reaffirms its commitment to making a positive impact on mental health, relationships, and wellbeing.

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .

Pancreatic Cancer Treatments Poised for Major Advances in 2024

Retrieved on: 
Wednesday, February 7, 2024
Gemcitabine, Pfizer, Bristol Myers Squibb, Investigational New Drug, Trial of the century, Pancreatic cancer, Patient, IND, Drug development, Incidence, ONC, FDA, SMP, TSX, BMY, Messenger, USP1, Woman, Cancer, HRD, Hope, News, Acquisition, Medivir, Oncolytics Biotech, PD-1, Pelareorep, Senior, TGF, Pancreatic Cancer Action Network, Pharmaceutical industry

VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group  -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer. As well, the deadly disease showed pancreatic cancer rates rising faster among women, causing increased alarm amongst doctors. Thankfully, 2023 also gave a lot of hope in terms of new treatments for the market that could reach US$36 billion by 2036, such as a potential mRNA vaccine, and other developments from biotech companies to lead into 2024, like Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC), Incyte Corporation (NASDAQ:INCY), Tango Therapeutics, Inc. (NASDAQ:TNGX), RayzeBio, Inc. (NASDAQ:RYZB) and its buyer Bristol-Myers Squibb Company (NYSE:BMY).

Key Points: 
  • VANCOUVER, BC, Feb. 7, 2024 /PRNewswire/ -- USA News Group -  One of the more worrying storylines of 2023 was the rising incidence of early-onset pancreatic cancer .
  • As well, the deadly disease showed pancreatic cancer rates rising faster among women , causing increased alarm amongst doctors.
  • After closing out 2022 with another fast track designation , Oncolytics Biotech Inc. (NASDAQ:ONCY) (TSX:ONC) and its flagship asset pelareorep continues to make strides in the battle against pancreatic cancer.
  • The results were enough to garner the support of the Pancreatic Cancer Action Network (PanCAN), who selected pelareorep to receive the US$5 million Therapeutic Accelerator Award .